Liquid Biopsy to Detect BRAFV600 Mutations in Advanced Cancers Shows Promise
Investigators found that cell-free DNA is released into circulation by cancer cells undergoing apoptosis or necroptosis in the primary or metastatic cancer lesions.
Diagnosis & Disease Information
BRAF mutations in non-small cell lung cancer
[Translational Lung Cancer Research] This research investigates the prevalence and clinicopathological features of BRAF mutations in non-small cell lung cancer (NSCLC) cases submitted for routine mutation testing.
For Melanoma, Pretreatment Influences Vemurafenib Therapy Outcomes
Type of pretreatment greatly influences vemurafenib therapy outcomes for patients with BRAF V600 mutated melanoma.
Survival Improved With Evolving Treatment Approaches for Metastatic Melanoma
Update on available treatment options and potential future developments for metastatic melanoma with and without BRAF mutations.
Nivolumab + Ipilimumab: ‘Unprecedented’ Survival Rates in Advanced Melanoma
CHICAGO, IL—Concurrent treatment with nivolumab plus ipilimumab resulted in “unprecedented” 2-year rates of overall survival in patients with advanced melanoma regardless of BRAF-mutation status.
Risk for New Primaries Higher in Stage III/IV Melanoma
Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas.
FDA Approves Trametinib/Dabrafenib Combination
The FDA has approved the use of trametinib in combination with dabrafenib for treatment of some types of melanoma.
BRAF Mutation May Increase Thyroid Cancer Death
Retrospective multicenter study shows PTC-related mortality increased with mutation
Targeting BRAF Mutation in Melanoma Treatment
Advanced, metastatic melanoma is an aggressive disease with a poor prognosis; but therapies targeting gene mutations may offer hope to some patients.
Novel ERK Inhibitor Shows Preclinical Promise Against BRAF, MEK-associated Drug Resistance
SCH772984 shows promise against tumor growth driven by BRAF and RAS mutations and might prove useful against tumor resistance to BRAF and MEK inhibitors, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2013.
- Loading...
Loading...
Next post in AACR 2013
Loading... 
Loading...